• Explore /
  • Poster
  • / MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.

MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.

Abstract Poster

Authors

null

Bernadett Szabados

Barts Cancer Institute, London, United Kingdom

Bernadett Szabados , Mark Kockx , Pieter-Jan Van Dam , Alejo Rodriguez-Vida , Ignacio Duran , Simon J. Crabb , Michiel Simon Van Der Heijden , Albert Font , Gwenaelle Gravis , Aaron Prendergast , Maurizio Perdicchio , Diana Stanoeva , Sofie Daelemans , Sanjeev Mariathasan , Joy S. Tea , Kelly Mousa , Romain Banchereau , Daniel Castellano , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02662309

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 541)

Abstract #

541

Poster Bd #

K22

Abstract Disclosures

Similar Posters

First Author: Deepak Kilari

First Author: Deepak Kilari

First Author: Nick Van Dijk

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

First Author: Jason Zhu